Abstract : China's first domestically developed drug for the treatment of HIV infection has been approved by the health authority of Ecuador to access the country's market, according to pharmaceutical producer Frontier Biotech.
NANJING, March 23 (Xinhua) — China’s first domestically developed
drug for the treatment of HIV infection has been approved by the health
authority of Ecuador to access the country’s market, according to
pharmaceutical producer Frontier Biotech.
Aikening, or albuvirtide for injection (ABT), was approved by China
Food and Drug Administration in 2018. It can be used with other
antiretroviral drugs to treat HIV patients, according to Frontier
Biotech, which is based in the east Chinese city of Nanjing.
The market access to Ecuador is the new drug’s first overseas market entry.
Data from clinical trials show that Aikening is effective against
major strains of HIV, including resistant viruses, and the efficacy is
The Chinese company said now it plans to export the drug to more than 60 countries in Asia, Africa, Europe and South America.
The global anti-HIV drug market grew from 22.9 billion U.S. dollars
in 2013 to 34 billion U.S. dollars in 2018, and is expected to further
expand to 46.7 billion U.S. dollars by 2023. Enditem
About Xinhua Silk Road
Xinhua Silk Road (en.imsilkroad.com) is the Belt and Road Initiative (BRI) portal. China’s silk road economic belt and the 21st century maritime silk road website, include BRI Policy, BRI Trade, BRI Investment, Belt and Road weekly, Know Belt and Road, and the integrated information services for the Belt and Road Initiative (BRI).
Source: China’s first domestically developed anti-HIV drug to go global